The Three Roles Open Now
As of early October 2026, Octant lists three open positions across its Greenhouse board and third-party aggregators: a Senior / Lead QA Analyst (Web3), an Events Lead, and a Social Media Lead. All three carry "Worldwide - remote" eligibility alongside a New York City anchor, and none disclose compensation bands. The roles have been posted for 34, 30, and 27 weeks respectively, a timeline that suggests either a deliberate, unhurried search or a pipeline that has yet to yield the right match.
The QA role is the only one with a published tech stack: JavaScript, TypeScript, Python, CI/CD via GitHub Actions, and test automation frameworks including Cypress, Playwright, and Selenium, all running against microservices orchestrated through Jira. The "Web3" qualifier in the title is striking for a company whose public platform combines high-throughput synthetic biology, generative chemistry, and AI/ML to map complex cellular mechanisms. It hints at either a blockchain-adjacent data integrity layer (perhaps for audit trails in regulated drug discovery) or an experimental track Octant has not publicly detailed. Either way, the stack reads like a modern web engineering shop, not a traditional lab IT support function.
The Events Lead and Social Media Lead sit on the communications and community side. Both are based in New York with remote flexibility, and both have lingered open for roughly half a year. That duration is notable for roles that typically fill faster in biotech, where conference circuits and investor storytelling create steady demand for event operations and brand voice. Octant's careers page frames its culture around "Octonauts" who "share a commitment to improve patients' lives and a penchant for conquering challenging problems," and it highlights organic, employee-initiated programs, including apprenticeships, a gender equity mentorship and sponsorship (GEMS) initiative, and a partnership with Berkeley's Y-Scholars, alongside clubs for tennis, sailing, board games, and D&D. The Events Lead would likely own the external face of that culture: scientific symposia, recruiting showcases, and the partner-facing gatherings that keep an "antedisciplinary" movement visible. The Social Media Lead would translate the platform's technical output, including synthetic biology screens, generative chemistry outputs, and AI/ML model releases, into narratives that recruit talent and signal credibility to pharma partners.
Together, the trio reveals a company staffing the edges of its core R&D engine. Octant's own description emphasizes that "whether you're a scientist, an engineer, or any other professional, we're working together to build a new type of drug discovery company." The open roles map to that "any other professional" bucket: quality assurance for the software layer that wraps the wet lab, events to convene the interdisciplinary community, and social media to broadcast the signal. No bench scientist, cheminformatician, or automation engineer appears in the current slate, though startup.jobs and Andreessen Horowitz's careers portal reference Scientist, Cheminformatics, Controller, and Analytical Chemistry Scientist listings that do not surface on Octant's live Greenhouse board as of the October recheck. Those may be filled, paused, or listed elsewhere.
The pattern suggests Octant is hardening its operational infrastructure before the next scientific hiring wave. A QA lead who can own test strategy across microservices implies a platform that ships code continuously. An events lead who can design experiences for a mixed audience of computational biologists, ML researchers, and pharma BD teams implies a partnership model that runs on convening power. A social media lead who can make "high-throughput synthetic biology" legible without dumbing it down implies a brand strategy tied to talent attraction as much as investor relations. All three roles demand fluency in Octant's technical language — the "antedisciplinary" vocabulary the company uses to describe its own work — without necessarily requiring a wet-lab background.
The Profile That Clears
The term "antedisciplinary" appears on the careers page with a link to a 2022 PLOS Computational Biology paper that argues for research structures that precede traditional disciplines rather than bridge them. At Octant, that translates to scientists who write production-grade code, engineers who design wet-lab assays, and operators who understand the thermodynamic constraints of a screening campaign. The company explicitly states that "scientists, engineers and operators — we are all working together to build a new type of company." Candidates who present as single-domain specialists, no matter how decorated, rarely clear the screen.
Ownership shows up in two forms. First, cultural ownership: "We also share a sense of ownership over the company culture and take initiative to make this an even more awesome place." The apprenticeship program, GEMS, and the Y-Scholars partnership were all started by employees, not leadership. Second, technical ownership: the biannual career development cycle requires every "Octonaut" to "reflect on their aspirations and devise concrete plans with their managers to make strides towards their goals." The company tracks internal mobility like a product metric: former individual contributors now lead technology development teams, drug discovery groups, and functions spanning synthetic biology, data science, automation, operations, and software engineering.
Growth orientation is non-negotiable. The careers page promises candidates will "continuously hone their craft by rising to the occasion in the face of challenging problems" and that the company is "pushing to evolve intellectually and to do the best work of our careers." This is not retention branding — it maps to the work. Octant engineers biology and chemistry at massive scale to modulate cellular function directly, targeting multifactorial diseases where the mechanism is the drug. The problems are undefined by design. People who need a spec before they start building self-select out.
Mission alignment carries weight because the patient connection is specific, not aspirational. "Of and by technologists. For patients." The lead program, OCT-980, is a first-in-disease oral small molecule correcting protein misfolding for rhodopsin gene mutations that cause RHO-adRP. A Phase 1a in healthy volunteers initiated in Q1 2026. Candidates who cannot articulate why that mechanism matters for that patient population, or who treat the biology as a black box, signal a mismatch.
Inclusion work is operationalized, not performative. The company states it is "passionate about encouraging the growth of the many underrepresented identities in STEM" and "strives to foster a culture of respect and empathy, do outreach in our community, and encourage everybody to pursue their career goals." It also admits: "We still have work to do, but we're focused on improving representation and the success of underrepresented backgrounds in our industry." That candor — naming the gap while describing the infrastructure built to close it — is itself a filter. It attracts candidates who have done the work elsewhere and repels those who treat DEI as a compliance checkbox.
The composite profile is rare by design: a builder who has shipped across disciplines, owns outcomes that aren't in their lane, learns in public, and treats the patient as the ultimate user. Octant's screen doesn't look for that profile; it looks for evidence the candidate already lives it.
Where the Market Stands
The compensation and hiring benchmarks that matter for a company like Octant don't live in a single spreadsheet. They sit at the intersection of two tightening talent markets: the computational biology premium that has persisted for years, and the engineering shortage now accelerating across biomanufacturing and process development. Any frontier biotech hiring today competes on three fronts simultaneously: against large pharma's cash, against AI-native startups' equity upside, and against a graduate pipeline that simply isn't producing enough people with the right hybrid training.
Stage remains the dominant variable. The Pillar VC and Pave analysis, one of the most cited datasets in the sector, segments compensation by capital raised precisely because a Series A company's offer looks nothing like a seed-stage one. Pre-seed and seed biotechs typically pay 20–35% below large pharma equivalents for the same title. Series A companies begin to close that base-salary gap, particularly for scientific leadership where competition with established players is direct and talent is scarce. By Series B and beyond, base salaries approach pharma-comparable levels for most functions, while equity grants shrink proportionally as the company de-risks and valuation climbs. A frontier biotech that demands both deep wet-lab fluency and the ability to build or adapt computational pipelines is effectively bidding for a Principal Scientist, plus the 10–20% premium that bioinformatics and computational biology roles command over wet-lab equivalents at the same seniority level.
Geography compounds the picture. US benchmarks overstate European market rates by 25–40% in absolute terms for most roles below VP level. If a company is building in Cambridge, London, or Basel, applying San Francisco Bay Area figures without adjustment will either blow the runway or make offers look uninformed. The same distortion appears in remote hiring: Recruits Lab data shows a 15–25% discount versus SF Bay Area rates for distributed roles, a gap that has held steady through Q4 2024. Any frontier biotech recruiting nationally or internationally has to model these differentials explicitly or lose candidates to better-calibrated offers.
The supply side is where the pressure shows most acutely. Engineering vacancy rates across pharma and biotech sit at roughly 12%, driven by a projected 15% increase in demand over the next two years from biomanufacturing and process engineering advances. Only 8,000 graduates emerge annually from relevant engineering programs, creating a shortfall of approximately 4,000 qualified candidates each year. Data science is tighter still: a 25% surge in demand meets an annual supply of roughly 6,000 new graduates, leaving a gap of around 3,000 professionals. Biostatistics and regulatory affairs face an estimated 10,000-candidate annual shortfall. These aren't abstract forecasts; they're the reason VP of Business Development roles at Series A now carry base with deal-linked bonus structures, and why Heads of Regulatory Affairs with IND track records command at the same stage. CMC leads and Clinical Operations Directors sit in similar bands. The market prices scarcity ruthlessly.
| Role | Stage | Base Salary (Range/Median) | Source / Notes |
|---|---|---|---|
| Principal Scientist (median) | Series A ($5–20M raised) | ~$155,000 median | Pillar VC & Pave analysis |
| VP of Business Development | Series A | $180,000–$220,000 base + deal-linked bonus | Market data |
| Head of Regulatory Affairs (IND track record) | Series A | $160,000–$200,000 | Market data |
| CMC Lead | Series A | $150,000–$185,000 | Market data |
| Clinical Operations Director | Series A | $150,000–$185,000 | Market data |
Attrition amplifies the problem. Average turnover across the industry has surged to 15%, fueled by competitive offers and the spread of hybrid work models that let candidates optimize for lifestyle without changing geography. Seventy-five percent of surveyed organizations now report formal diversity and inclusion programs, particularly targeting leadership roles, signaling that retention has become a strategic priority, not an HR checkbox. Companies responding with milestone-linked vesting (tying partial equity to IND filing, Phase I completion, or partnership execution) and structured development programs are the ones holding onto the hybrid profiles that frontier biotech needs most.
The net effect: a company screening for the rare blend of technical depth and entrepreneurial agility isn't just competing on salary. It's competing on clarity: stage-appropriate equity, cap table transparency, and whether the role actually exists at the intersection of wet and dry lab or just claims to. The benchmarks say the talent exists. The vacancy rates say it's already employed. The winning offers are the ones that prove they understand both realities.
The Kicker
Octant's three roles have sat open for 27 to 34 weeks not because the company is picky, but because the market has not yet produced enough people who can write Cypress tests for a microservices layer one day, design a scientific symposium for computational biologists and pharma BD the next, and translate a generative chemistry release into a narrative that recruits the next antidisciplinary builder — all while understanding why a rhodopsin misfolding correction matters to a patient waiting for OCT-980. The bottleneck is the education system, the career ladder, and the industry's own imagination — all of which still treat biology, engineering, and operations as separate departments. Octant's open requisitions are a measure of that gap. They will stay open until the workforce catches up to the company's definition of the work.
Working in frontier tech? Zero G Talent tracks the openings: see every open ASML role, browse frontier tech jobs, openings at Stripe, and the people building the field.